Ignite Creation Date:
2025-12-24 @ 11:31 PM
Ignite Modification Date:
2026-01-02 @ 1:33 AM
Study NCT ID:
NCT03148756
Status:
TERMINATED
Last Update Posted:
2022-04-25
First Post:
2017-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-04
Completion Date Type:
ACTUAL
First Submit Date:
2017-05-09
First Submit QC Date:
None
Study First Post Date:
2017-05-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2018-08-08
Results First Submit QC Date:
None
Results First Post Date:
2018-09-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-08-07
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-03-28
Last Update Post Date:
2022-04-25
Last Update Post Date Type:
ACTUAL